National Institutes of Health (NIH)

151 articles with National Institutes of Health (NIH)

• Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies

  10/21/2019

  ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.

• Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma

  10/17/2019

  Rafael will provide the compound for the study.

• UCD Researcher wins US-Ireland grant for personalised nutrition project with Harvard and QUB

  10/14/2019

  Professor Lorraine Brennan from University College Dublin is delighted to have been awarded a US-Ireland grant, funded by the Health Research Board (HRB), to the tune of almost €1 million.

• Emmes Awarded New NIH Contracts that Address the Nation's Opioid Addiction Crisis

  10/10/2019

  The Company is Hiring Additional Staff to Support its Awards Totaling Over $9 Million

• NIH Grant Awarded to Akelos Collaborator, Funds Work to Develop Non-Opioid Drugs for Neuropathic Pain

  10/4/2019

  A grant from the National Institutes of Health awarded to a Weill Cornell Medicine investigator will bolster Akelos Inc.-supported research to develop a non-opioid alternative to treat chronic and neuropathic pain.

• Imbed Awarded $1.5 Million NIH Grant to Fight Biofilms in Wounds

  9/27/2019

  Imbed Biosciences, Inc. announced that it has been awarded a $1.5 million two-year Small Business Innovation Research grant from the National Institute for Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.

• Indivior awarded NIH HEAL grant to undertake clinical development of C4XD’s Orexin-1 for treatment of Opioid Use Disorder

  9/27/2019

  C4X Discovery Holdings plc is pleased to note Indivior PLC’s announcement that the National Institutes of Health has granted Indivior's application entitled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

• Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative

  9/26/2019

  Indivior PLC announces that the National Institutes of Health has granted Indivior's application entitled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

• Hesperos Human-on-a-Chip Technology Awarded First Phase of $3.8 Million Milestone-based NIH Grant to Study Opiate Overdoses in Collaboration With UCF

  9/26/2019

  Grant is part of the Helping to End Addiction Long-Term Initiative (NIH HEAL Initiative) launched in 2018

• Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain

  9/26/2019

  Company to receive up to $8 million for its Kv7 platform as part of federal program to apply scientific solutions to reverse the national opioid crisis

• Versatope Awarded up to $17.9M for a Universal Influenza Vaccine

  9/25/2019

  The award is through the Broad Agency Announcement (BAA) program to advance Versatope's universal influenza vaccine candidate.

• NIH funds new centers to expand and diversify the human reference genome

  9/25/2019

  The UC Santa Cruz Genomics Institute will play a leading role in the ambitious new Human Pangenome Reference Sequence Project

• Knopp Biosciences Receives Year 4 Renewal of NIH Blueprint Grant Award for Advancing the Kv7 Activator KB-3061 in a Rare Neonatal Epilepsy

  9/25/2019

  Knopp’s lead Kv7 platform candidate advancing toward clinical studies in KCNQ2 epileptic encephalopathy

• Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

  9/17/2019

  Inovio Pharmaceuticals, Inc. announced that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health grant in support of innovative research to tackle antimicrobial resistance employing Inovio's DNA-encoded monoclonal antibodies platform.

• Crestone, Inc. (Boulder) Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate

  9/12/2019

  Crestone, Inc. announced a Contract Award from the National Institutes of Health focused on the Phase 2 clinical development of its small molecule drug candidate, CRS3123, for the treatment of Clostridioides difficile infections.

• Fannin Awarded $1 Million NIH Grant For Continued Development of Asthma Drug

  8/21/2019

  The National Institutes of Health has awarded Fannin Innovation Studio® a $1 million grant to continue development of PM-43I, the company’s anti-asthma drug, in collaboration with portfolio company Atrapos Therapeutics, LLC., as a more effective alternative to steroids.

• NIH to Evaluate Iclaprim Activity against Listeria

  8/20/2019

  Motif Bio plc announced that the Company will be utilising NIAID's1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections.

• Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

  8/15/2019

  Soligenix, Inc. announced that the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, has awarded Soligenix a Phase I Small Business Innovation Research of approximately $150,000 to support the evaluation of SGX942 in pediatric indications.

• MBio Diagnostics Announces Two Contracts for Sepsis Test Development

  8/1/2019

  Sepsis tests will be developed in collaboration with the Cincinnati Children’s Hospital Medical Center (CCHMC) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to address the critical need for more effective sepsis patient management in clinical and field settings

• DSFederal Expands Work With NIH, Awarded Contract for Scientific and Program Support Services to OER

  7/30/2019

  DSFederal announced that it has expanded its long history of work supporting the National Institutes of Health through a new contract to provide a wide range of scientific and program support services, including highly qualified technical and scientific analytics experts, to the Office of Extramural Research.